Salute e Benessere

Chromatography Reagents Market Worth $11.5 billion | MarketsandMarkets™

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=435 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=435 Browse in-depth TOC on "Chromatography Reagents Market" 160 - Tables 57 - Figures 258 - Pages Chromatography Reagents Market Scope: Solvent segment is expected to register the substantial share by reagent type of chromatography reagents market The solvents segment is...
PR Newswire
29/02/2024

Alamar Biosciences and ALZpath, Inc. Announce Strategic Supply Agreement for…

Under the terms of the agreement, Alamar Biosciences will use ALZpath's pTau217 antibody in its NULISAqpcr™ pTau-217 Assay, as well as in their multiplexed NULISAseq™ CNS Disease Panel 120, further fortifying Alamar's commitment to delivering best-in-class solutions to the neuroscience community. This collaboration leverages Alamar's highly sensitive, automated NULISA™ platform and ALZpath's broad expertise in Alzheimer's disease diagnostics, creating a synergistic partnership that aims to…
PR Newswire
29/02/2024

LILYSILK Top Choice for Kelly Clarkson on Her Popular Daytime Talk Show

On January 18, dressed in the sophisticated Black Vivi Knit Dress from LILYSILK paired with golden accessories, Kelly performed En Vogue's classic Don't Let Go (Love). This off-the-shoulder silhouette is made from spun silk yarn, with the pleated skirt designed with rib-knit technique creating a sense of fluidity. OnJanuary 18, dressed in the sophisticated BlackVivi Knit Dressfrom LILYSILK paired with golden accessories, Kelly performed En Vogue's classicDon't Let Go (Love). This...
PR Newswire
29/02/2024

AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and…

Company continues progress across Ampligen ®clinical development programs Growing body of promising data demonstrates Ampligen's potential to address multiple high-value indications OCALA, Fla., Feb.29, 2024(GLOBE NEWSWIRE) -- AIM ImmunoTech Inc.(NYSE American: AIM) (“AIM” or the “Company”) today highlighted recent accomplishments and provided a business outlook. AIM's dsRNA product candidate, Ampligen ®(rintatolimod), is being evaluated as a combinational therapy for the...
Nasdaq GlobeNewswire
29/02/2024

SpringWorks Therapeutics Announces European Medicines Agency Validation for…

Application based on Phase 3 DeFi trial in which nirogacestat significantly improved progression-free survival and objective response rate compared to placebo, with rapid and sustained improvements in symptom burden including pain, physical and role functioning, and quality of life “The validation of our marketing authorization application is an important step towards bringing nirogacestat to patients with desmoid tumors in the European Union who currently do not have an approved therapy,”...
Nasdaq GlobeNewswire
29/02/2024

MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent…

MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10 A successful year including the announcements of positive data from two Phase 2 trials of sonelokimab in hidradenitis suppurativa (HS), at 12 and 24 weeks, and active psoriatic arthritis (PsA), at 12 weeks, supporting a potential best-in-class profile across two key indications Phase 3 preparation for sonelokimab in HS nearing completion, following...
Nasdaq GlobeNewswire
29/02/2024

Evaxion to Host R&D Day on March 19, 2024, Highlighting its Latest Technology…

/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announces that it will host a Research & Development (R&D) Day focusing on its core AI-Immunology™ platform on March 19, 2024, at 14:00 - 18:00 CET / 8:00 a.m. - 12:00 a.m. EST. The R&D Day will feature a series of talks from Evaxion's scientists and bioinformaticians, providing insights into Evaxion's validated AI-Immunology™ platform...
Nasdaq GlobeNewswire
29/02/2024

Compass Pathways Announces Fourth Quarter 2023 Financial Results and Business…

Highlights: COMP360 phase 3 pivotal program ongoing; COMP005 trial top-line data now expected in fourth quarter 2024, COMP006 remains on track for top-line data in mid-2025Teri Loxam to assume Chief Financial Officer role on March 1, 2024Cash position of $220.2 million at December 31, 2023, additional $31.4 million net cash raised to date in first quarter 2024Conference call February 29 at 8:00 am ET (1:00 pm UK) Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a...
Nasdaq GlobeNewswire
29/02/2024

AB Science will host a live webcast on Monday March 4, 2024, from 6.30pm to…

PRESS RELEASEAB SCIENCE WILL HOST A LIVE WEBCAST ON MONDAY MARCH 4, 2024 FROM 6.30PM TO 7.30PM CETParis, 29 February, 2024, 11.30am CETAB Science SA(Euronext – FR0010557264 – AB) will host a live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CET. The agenda of this live webcast will be to provide status and perspective on the following topics: Conditional approval of masitinib in ALS with EMA and Health CanadaPartnership strategyMasitinib platform clinical...
Nasdaq GlobeNewswire
29/02/2024

DONESTA® safety study for menopause completes treatment phase and advances to…

DONESTA ®safety study for menopause completes treatment phase and advances to data management & reporting phaseMithra on-track for completion of Phase 3 study for DONESTA® to treat vasomotor symptoms (VMS) in menopauseMithra begins patient recruitment for the three proof-of-concept studies to explore treatment of symptoms beyond VMSLiege, Belgium, 28 February 2024 – 17:45 CET– Mithra (Euronext Brussels: MITRA), a company dedicated to women's health,...
Nasdaq GlobeNewswire
29/02/2024

dsm-firmenich publishes 2023 Integrated Annual Report

The report provides detailed information on the Group's performance in 2023, including progress on the integration, delivery of synergies, and sustainability commitments. In addition, the report includes reviews of each Business Unit, case studies of groundbreaking customer collaboration, and insight into the company's positive business impacts for climate and nature, nutrition and health, and people. The report provides detailed information on the Group's performance in 2023, including...
PR Newswire
29/02/2024

Bringing confident diagnosis to more patients at low cost: Philips launches new…

New CT 5300 system provides more accurate and reliable imaging results to better manage increase in complex cardiac cases where precise patient diagnosis is crucial Philips' latest innovation leverages the power of AI at every stage in CT scanner operation to enhance productivity and diagnostic capabilities of high-throughput, short-staffed radiology departments Amsterdam, the Netherlands and Vienna, Austria – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health...
Nasdaq GlobeNewswire
29/02/2024

Biosense Webster Announces CE Mark approval in Europe for VARIPULSE™ Pulsed…

"CE mark approval of the VARIPULSE™ Platform represents a significant advance in catheter ablation technology, allowing electrophysiologists to offer patients in Europe pulsed field ablation treatment with real-time integrated 3D mapping," said Tom De Potter,***MD, Associate Director, Cardiovascular Center, OLV Hospital Aalst, Belgium. "Significantly, the VARIPULSE™ Platform is fully integrated with the CARTO™ 3 System, enabling a simplified workflow with minimal fluoroscopy time…
PR Newswire
29/02/2024

Ariceum Therapeutics Granted UK Authorisation to Conduct Phase I Clinical Study…

Manfred Rüdiger, Chief Executive Officer at Ariceum Therapeutics, said: "It is a tremendous achievement for Ariceum to receive CTA approval by the MHRA so soon after submission. Glioblastoma is the most common and most aggressive type of malignant brain tumour in adults, with a very poor prognosis for survival and currently no cure. Following the integration of Theragnostics into Ariceum and promising pre-clinical results, we welcome the opportunity to be the first company to trial Auger…
PR Newswire
29/02/2024

RAMSAY SANTE :half-year financial report as at end of December 2023 disposal

Paris, February 29, 2024 RAMSAY SANTE Half-year Financial Report as at end of December 2023 disposal This document is available on RAMSAY SANTE Internet site :http://www.ramsaysante.fr About Ramsay Santé :Ramsay Santé is leader in private hospitalisation and primary care in Europe. The Group has 38,000 employees and works with nearly 9,300 practitioners to treat more than 12 million patients per year in its 465 facilities and 5 countries:...
Nasdaq GlobeNewswire
29/02/2024

BioInnovation Institute welcomes twelve new companies to its Venture Lab program

Bobby Soni, Chief Business Officer at BioInnovation Institute, said:"Working across the planetary, therapeutics, women's health, health tech and quantum industries, these twelve start-ups have demonstrated the drive and tenacity that align with BII's mission in creating innovative solutions to address current challenges in these sectors. We once again look forward to supporting these start-ups in bringing their innovations into fruition by providing our knowledge, network, funding, and…
PR Newswire
29/02/2024

BioArctic: Latest data on lecanemab to be presented at the 2024 AD/PD™ congress

At AD/PD, BioArctic will present one oral presentation and one poster on lecanemab, both focused on the binding properties of lecanemab to various types of Aβ of lecanemab compared to several other Aβ antibodies. The company will also have two other posters related to Alzheimer's disease. At AD/PD, BioArctic will present one oral presentation and one poster on lecanemab, both focused on the binding properties of lecanemab to various types of Aβ of lecanemab compared to several other Aβ…
PR Newswire
29/02/2024

Pharming Group to report fourth quarter and full year 2023 financial results on…

Leiden, The Netherlands, February 29, 2024:Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) fourth quarter and full year 2023 financial results, for the period ended December 31, on Thursday, March 14, 2024. Pharming will host a presentation for analysts and investors at 13:30 CET/08:30 am EDT on March 14, 2024. To participate in the conference call, please register in advance using the link below. Once registered,...
Nasdaq GlobeNewswire
29/02/2024

Rare Disease Day 2024 - Call for greater awareness of X-linked…

The film can be found on Neuraxpharm's and Minoryx's websites, YouTube and LinkedIn channels. Watch the film here. The film can be found on Neuraxpharm's and Minoryx's websites, YouTube and LinkedIn channels. Watch the filmhere. Dr. Jörg- Thomas Dierks, Chief Executive Officer of Neuraxpharm, said: "The impact this disease has on patients and their families cannot be overstated. At Neuraxpharm, we are committed to bringing better treatment to patients so that we can improve the lives...
PR Newswire
29/02/2024

ONWARD® Medical Awarded 10th Breakthrough Device Designation for Brain-Computer…

Award gives priority US regulatory review to Company's ARC-BCI™ System This is the tenth FDA BDD awarded to ONWARD Medical. The designation is reserved for novel, cutting-edge therapies addressing an unmet need and provides many potential regulatory and reimbursement advantages. This latest award gives ONWARD Medical priority FDA review, the opportunity to interact with FDA experts throughout the pre-market regulatory review phase, and the potential to seek additional reimbursement for its...
Nasdaq GlobeNewswire
29/02/2024

BioSenic S.A. : Information on the total number of voting rights and shares

PRESS RELEASE – REGULATED INFORMATIONMont-Saint-Guibert, Belgium, 29 February 2024, 7.00 am CEST –BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, today announces an increase in the total number of voting rights and shares as a result of the issuance of new shares. The following information is published in accordance with Article 15 of the Belgian Law of 2 May 2007 on the...
Nasdaq GlobeNewswire
29/02/2024

IBA signs contract with IAEA for the installation of a Cyclone® KEY in Benin…

Contract with IAEA demonstrates Cyclone® KEY's accessibility for low- and middle-income countriesLouvain-la-Neuve, Belgium, February 29, 2024 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world's leading provider of radiopharmaceutical production solutions, is pleased to announce that it has signed a contract for a Cyclone ®KEY cyclotron with the International Atomic Energy Agency (IAEA). This cyclotron will be...
Nasdaq GlobeNewswire
29/02/2024

U.S. CDC Advisory Committee (ACIP) Recommends Use of Valneva's Single-Dose…

U.S. CDC Advisory Committee (ACIP) Recommends Use of Valneva's Single-Dose Chikungunya Vaccine IXCHIQ ® Recommendation for use in travelers and laboratory workers follows U.S. Food and Drug Administration (FDA) approval in November 2023 1 IXCHIQ ® is the first and only vaccine approved to address this unmet medical need in adults aged 18 years and older who are at increased risk of exposure to the chikungunya virusSaint-Herblain (France), February 29, 2024–Valneva SE...
Nasdaq GlobeNewswire
29/02/2024

Sandoz US subsidiaries resolve generic drug antitrust class action litigation…

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASESandoz US to pay USD 265 million in exchange for full release of all claims by the classResolves all federal antitrust damages for direct purchaser class plaintiffs' claims in this litigation, if approved by CourtBasel, February 29, 2024– Sandoz Inc. and its subsidiary Fougera Pharmaceuticals Inc. (together, “Sandoz US”) – both indirect subsidiaries of Sandoz Group AG – have entered into a...
Nasdaq GlobeNewswire
29/02/2024
Altri  Comunicati